恩替卡韦和阿德福韦酯治疗慢性乙型肝炎的随机对照研究  

Random study of Entecavir and Adefovir dipivoxil in patients with chronic hepatitis B

作　　者：黄浩[1] 许夕海[1] 马泰[1] 郜玉峰[1] 程君[1] 叶英[1] 周仲松[1] 谢琴秀[1] 魏少峰[1] 苏菲[1] 李家斌[1] 

机构地区：[1]安徽医科大学第一附属医院感染病科,合肥230022

出　　处：《中国实用内科杂志》2010年第6期548-549,共2页Chinese Journal of Practical Internal Medicine

基　　金：国家自然科学基金(30700698)

摘　　要：目的比较恩替卡韦(ETV)与阿德福韦酯(ADV)治疗慢性乙型肝炎的近期疗效和不良反应。方法将2007年6月至2008年5月安徽医科大学第一附属医院感染病科收治的99例慢性乙型肝炎患者,随机分为治疗组和对照组,观察治疗中DNA定量等指标变化。结果比较两组治疗后24、48、96周HBVDNA阴性率,差异有统计学意义(P<0.05)。与治疗起始相比,治疗组24、48周HBVDNA下降幅度均比对照组大,差异有统计学意义(P<0.05)。试验中治疗组未发现病毒学反弹,对照组出现1例;两组HBVDNA载量500～999copies/mL,300～499copies/mL和<300copies/mL者差异无统计学意义。两组HBeAg(+)患者HBVDNA阴性率差异有统计学意义(P<0.05);试验中未发现HBeAg转换。结论 ETV治疗慢性乙型肝炎早期抗病毒活性明显优于ADV,未见明显不良反应。Objective To study the short-term efficacy and safety of the treatment with entecavir （ETV） and adefovir dipivoxil （ADV） for patients with chronic hepatitis B through randomized controlled trial. Methods 99 patients were randomly divided into treatment group and control group, and the changes of HBV DNA and so on were observed. Results The negative rate of HBV DNA after 24 weeks,48 weeks and 96weeks in 2 groups had statisticaly significance （P 〈 0. 05 ）. Compared with control group, in the initial HBV DNA,in the treatment group decreased more on the 24 weeks and 48 weeks （P 〈 0. 05 ）with one case of allergic reactions after ADV treatment; HBV DNA in 500 - 999 copies/mL , 300 - 499 copies/mL and 〈 300 copies/mL had no difference at the three intervals （ P 〉 0. 05 ） ; the negative rate of HBeAg （ ＋ ） patients was statistically significant （ P 〈 0. 05 ） ; there was no HBeAg conversion in this study. Conclusion Anti-viral activity of ETV is significantly superior to ADV in early phase when chronic hepatitis B is treated and it has no significant adverse reactions.

关 键 词：恩替卡韦 阿德福韦酯 慢性乙型肝炎 

分 类 号：R5[医药卫生—内科学]